Profile data is unavailable for this security.
About the company
Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT3645. PRT3789 is a highly selective degrader of SMARCA2 protein, which along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT3645 is a brain and tissue penetrant molecule that potently targets CDK4/6 with a biased selectivity for CDK4. PRT2527 is designed to be a potent and selective CDK9 inhibitor. Its MCL1 candidate, PRT1419, is designed to be a potent and selective inhibitor of the anti-apoptotic protein, MCL1.
- Revenue in USD (TTM)0.00
- Net income in USD-129.85m
- Incorporated2016
- Employees128.00
- LocationPrelude Therapeutics Inc175 Innovation BoulevardWILMINGTON 19805United StatesUSA
- Phone+1 (302) 467-1280
- Fax+1 (302) 658-3989
- Websitehttps://preludetx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Agenus Inc | 159.63m | -223.67m | 129.22m | 389.00 | -- | -- | -- | 0.8095 | -11.27 | -11.27 | 8.03 | -11.42 | 0.4723 | -- | 154.98 | 410,357.30 | -68.45 | -55.02 | -281.52 | -115.31 | 99.51 | -- | -144.94 | -102.92 | -- | -0.9185 | -- | -- | 59.47 | 33.56 | -11.66 | -- | 22.58 | -- |
| Coherus Biosciences Inc | 308.13m | -29.34m | 130.19m | 246.00 | -- | -- | -- | 0.4225 | -0.4014 | -0.4014 | 2.74 | -0.7301 | 0.5385 | 2.86 | 1.95 | 1,006,974.00 | -5.13 | -21.43 | -11.46 | -29.32 | 41.51 | 79.01 | -9.52 | -36.56 | 1.07 | -4.02 | 1.47 | -- | 21.89 | -- | 18.46 | -- | -18.37 | -- |
| Fractyl Health Inc | 119.00k | -65.88m | 130.36m | 102.00 | -- | 1.84 | -- | 1,095.48 | -1.37 | -1.37 | 0.0025 | 1.48 | 0.0013 | 1.02 | 3.05 | 1,166.67 | -59.97 | -- | -67.93 | -- | 41.18 | -- | -46,620.17 | -- | 7.46 | -- | 0.2862 | -- | -- | -- | -48.15 | -- | -- | -- |
| TriSalus Life Sciences Inc | 24.74m | -57.21m | 134.54m | 112.00 | -- | -- | -- | 5.44 | -1.70 | -1.70 | 0.8372 | -0.8892 | 1.00 | 1.23 | 7.28 | 220,848.20 | -220.73 | -- | -2,149.76 | -- | 87.65 | -- | -219.71 | -- | 2.04 | -100.87 | -- | -- | 49.31 | -- | -26.51 | -- | -- | -- |
| Kodiak Sciences Inc | 0.00 | -197.68m | 135.75m | 111.00 | -- | 0.6328 | -- | -- | -3.77 | -3.77 | 0.00 | 4.08 | 0.00 | -- | -- | 0.00 | -39.89 | -31.73 | -44.14 | -33.61 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 21.97 | -- | 134.76 | -- |
| Vigil Neuroscience Inc | 0.00 | -83.84m | 135.99m | 64.00 | -- | 1.51 | -- | -- | -2.12 | -2.12 | 0.00 | 2.27 | 0.00 | -- | -- | 0.00 | -59.07 | -- | -63.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.98 | -- | -- | -- |
| Prelude Therapeutics Inc | 0.00 | -129.85m | 140.31m | 128.00 | -- | 0.5898 | -- | -- | -1.80 | -1.80 | 0.00 | 4.32 | 0.00 | -- | -- | 0.00 | -51.44 | -47.21 | -55.69 | -51.07 | -- | -- | -- | -- | -- | -- | 0.0028 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| aTyr Pharma Inc | 588.00k | -57.90m | 141.74m | 56.00 | -- | 1.74 | -- | 241.05 | -0.9047 | -0.9047 | 0.0092 | 1.08 | 0.0049 | -- | 0.4034 | 10,500.00 | -48.51 | -45.45 | -53.89 | -52.74 | -- | -- | -9,846.26 | -784.19 | -- | -- | 0.0202 | -- | -96.60 | -- | -11.14 | -- | 47.98 | -- |
| Outlook Therapeutics Inc | 0.00 | -94.05m | 141.93m | 24.00 | -- | -- | -- | -- | -8.12 | -8.12 | 0.00 | -3.57 | 0.00 | -- | -- | 0.00 | -205.48 | -214.69 | -- | -1,843.48 | -- | -- | -- | -3,043.92 | -- | -26.89 | -- | -- | -- | -- | 10.70 | -- | -- | -- |
| Century Therapeutics Inc | 2.04m | -131.39m | 144.02m | 152.00 | -- | 0.6472 | -- | 70.53 | -2.04 | -2.04 | 0.031 | 2.63 | 0.0049 | -- | -- | 13,434.21 | -31.52 | -- | -33.04 | -- | -- | -- | -6,434.23 | -- | -- | -- | 0.00 | -- | -57.01 | -- | -4.38 | -- | -- | -- |
| CervoMed Inc | 9.65m | -5.04m | 144.19m | 8.00 | -- | 2.89 | -- | 14.94 | -0.4796 | -0.4796 | 1.55 | 6.06 | 0.2803 | -- | -- | 1,206,660.00 | -14.64 | -53.67 | -15.71 | -58.89 | -- | -- | -52.24 | -949.54 | -- | -- | 0.00 | -- | -- | -- | 86.07 | -- | -- | -- |
| Fennec Pharmaceuticals Inc | 48.89m | 2.74m | 144.73m | 36.00 | 135.99 | -- | 52.92 | 2.96 | 0.0389 | 0.0389 | 1.75 | -0.0497 | 1.18 | 1.21 | 6.63 | -- | 6.62 | -73.43 | 7.70 | -84.32 | 95.55 | -- | 5.59 | -383.28 | 7.75 | 1.87 | 1.05 | -- | 1,284.50 | -- | 32.34 | -- | -- | -- |
| ProQR Therapeutics NV | 20.88m | -24.04m | 145.39m | 157.00 | -- | 4.09 | -- | 6.96 | -0.2956 | -0.2956 | 0.2566 | 0.4352 | 0.1406 | -- | -- | 132,979.00 | -15.98 | -35.51 | -20.63 | -40.51 | -- | -- | -113.62 | -926.31 | -- | -- | 0.3687 | -- | 118.51 | 10.58 | 56.35 | -- | 34.45 | -- |
| Invivyd Inc | 2.26m | -203.84m | 145.72m | 94.00 | -- | 1.04 | -- | 64.36 | -1.80 | -1.80 | 0.0199 | 1.18 | 0.0092 | -- | 1.13 | 24,085.11 | -82.73 | -- | -96.25 | -- | 96.11 | -- | -9,003.40 | -- | 4.57 | -- | 0.00 | -- | -- | -- | 17.68 | -- | -- | -- |
| Repare Therapeutics Inc | 68.68m | -68.52m | 148.56m | 179.00 | -- | 0.7294 | -- | 2.16 | -1.63 | -1.63 | 1.61 | 4.80 | 0.2558 | -- | 6.34 | 383,703.90 | -25.52 | -23.40 | -30.30 | -26.37 | -- | -- | -99.76 | -162.76 | -- | -- | 0.00 | -- | -61.21 | -- | -222.91 | -- | 27.16 | -- |
| Quantum-Si Inc | 1.70m | -89.35m | 150.90m | 159.00 | -- | 0.6467 | -- | 88.66 | -0.6302 | -0.6302 | 0.012 | 1.64 | 0.0057 | 0.2321 | 3.68 | 10,704.40 | -29.89 | -- | -30.99 | -- | 53.41 | -- | -5,249.65 | -- | 20.13 | -- | 0.00 | -- | -- | -- | 27.55 | -- | -- | -- |
Data as of Sep 20 2024. Currency figures normalised to Prelude Therapeutics Inc's reporting currency: US Dollar USD
35.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Baker Bros. Advisors LPas of 30 Jun 2024 | 10.12m | 24.01% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 999.50k | 2.37% |
| BlackRock Fund Advisorsas of 30 Jun 2024 | 895.49k | 2.12% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 30 Jun 2024 | 874.46k | 2.07% |
| Massachusetts Financial Services Co.as of 30 Jun 2024 | 522.38k | 1.24% |
| Geode Capital Management LLCas of 30 Jun 2024 | 361.95k | 0.86% |
| Sio Capital Management LLCas of 30 Jun 2024 | 320.39k | 0.76% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 30 Jun 2024 | 242.73k | 0.58% |
| SSgA Funds Management, Inc.as of 30 Jun 2024 | 211.75k | 0.50% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 206.60k | 0.49% |
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
